31st March 2023
Lung Cancer is associated with the uncontrolled growth of lung tissue that leads to impairment of normal lung function. Lung cancer exists majorly in two forms such as small-cell lung cancer (SCLC), and non-small-cell lung cancer (NSCLC). According to recent statistics, the prevalence of SCLC is about 10-15 %. On the other hand, 80-85 % are NSCLC. To prevent cancer growth, the removal of tumors through surgery is usually suggested by physicians. It further depends on the type, location, and stage of the cancer condition. Lung cancer surgery involves the removal of a tumor with some amount of surrounding lung tissue and lymph nodes near the region of the tumor.
Advancements in surgery for lung cancer have been ongoing in recent years, with the development of minimally invasive procedures, such as video-assisted thoracoscopic surgery (VATS) and robot-assisted surgery. These techniques can lead to shorter hospital stays, faster recovery times, and reduced postoperative pain and complications compared to traditional open surgery. However, the best course of treatment for any individual with lung cancer will depend on various factors and should be determined by a healthcare professional.
According to the World Health Organization (WHO), lung cancer was the most commonly diagnosed cancer in the world in 2020, accounting for 11.4% of all cancer cases. It is also the leading cause of cancer death worldwide, accounting for 18.0% of all cancer deaths. The prevalence of lung cancer is influenced by several factors, including smoking, exposure to environmental pollutants, family history of lung cancer, and genetic predisposition. Smoking is the leading cause of lung cancer, accounting for about 85% of all cases. Other risk factors include exposure to radon, asbestos, and air pollution.
The incidence of lung cancer increasing every year that created a demand for lung cancer surgery among seriously affect patients. According to physicians, surgery is a primary option before other treatment categories. Since it is necessary to remove the pain-causing tumor mass that further improves the effectiveness of other treatments after surgery. This developed a greater market size for lung cancer surgery as defined in the current forecast period.
The Lung Cancer Surgery Market has reached a value of $5.89 billion in 2020. This market is expected to grow from $6.19 billion in 2023 to $8.76 billion in 2030 with a CAGR of 5.1% in the forecast period of 2023-2030. This market is estimated based on different key pointers that attributes to the growth which are product types including Surgical Instruments, Monitoring & Visualizing Systems, Endosurgical Equipment, Robotic-Assisted Thoracic Surgery Systems, and Other, surgical procedures such as Thoracotomy & Minimally Invasive Surgery, and end-user which include Hospitals, Ambulatory Surgical Centres, Academic & Research Laboratories, Speciality Cancer Care Centres & Other.
Leading companies such as Accuray International, GE Healthcare, Johnson and Johnson, Olympus Corporation, and Siemens Healthineers AG are continuously focused on bringing new medical instruments and devices to make a significant profit that enables the growth of the lung cancer surgery market.
The Thoracotomy segment has shown a major impact on this market growth. Segmentectomy is the type of surgical treatment extensively used in thoracotomy surgery type and a better option for NSCLC. It is suggested specifically for patients with less lung capacity after being affected by lung cancer. This method is gaining popularity due to better outcomes, less pain, and a quicker recovery time than traditional surgical techniques. The segmentectomy procedure has a good success rate for removing localized tumors and cancers with higher survival rates, with the retention of organ functions to some extent, and these benefits are expected to drive the growth of the lung cancer market.
According to the American Cancer Society, the prevalence of lung cancer among the population of the US is 238,340 new cases of lung cancer in 2023 and the death count is about 127,070. Of the majority of cancer fatalities in the US about 1 in 5 are caused by lung cancer, which is the most common type of cancer. This degree of lung cancer burden in this country drives the market need for sophisticated medical instruments and advanced surgery equipment for lung cancer surgery. Further, it enhances the market share of prominent companies that deploy these services and contributes to the elevation of the Lung Cancer Market in the forecast period.
Growing demand for minimally invasive techniques is advantageous for future economic growth and the expansion of the healthcare sector, and it is immensely helpful because it has been widely accepted by physicians due to its reduced surgical complications, and a substantial influence on the development of better & more sophisticated medical techniques available on the market. The international demand for lung cancer surgery has opened up larger opportunities as a result of the rise in minimally invasive procedures.
The pioneer companies working in developing medical equipment and instruments for cancer surgery should focus majorly on the recent advancement in the surgical field, knowing the needs of surgeons, challenges involved in the surgery, pricing, and operational cost. Bringing new innovations and diminishing the risk associated with surgical procedures highly contributes to the market growth of lung cancer in the upcoming years.